Researchers at the Francis Crick Institute have mapped all the possible outcomes of changes to a tumor-suppressing gene called VHL, the first step in a huge research endeavor to unpick the outcomes of tens of thousands of genetic variations in genes associated with cancer.
Janux shares up 90% as T cell engager shows early signs of PSA response in prostate cancer
Janux Therapeutics’ share price has rocketed on the back of Phase Ia dose-escalation data for its tumor-activated T cell engager in advanced or metastatic castration-resistant
February 28, 2024